INTRODUCTION 1

MATERIAL AND METHODS 1 2
Plasmids 3 The pAC1-M2-WPRE plasmid comprising AAV ITRs bracketing the bidirectional 4 tetracycline-responsive cassette expressing both rtTAM2 and EGFP and the Woodchuck 5 hepatitis virus posttranscriptional regulatory element (WPRE) (Donello et al., 1998) 6 introduced immediately downstream to the rtTAM2 sequence has been described previously 7 (Chtarto et al.,2007) . 8 9
Recombinant viruses 10
High titers of recombinant rAAV2/1-rtTAM2-EGFP, rAAV2/1-rtTAM2-WPRE-EGFP and 11 recombinant rAAV2/1-CMV-EGFP viral stocks were produced at the Gene Vector 12
Production Network (Laboratoire de Thérapie Génique, Nantes, France) as described (Salvetti 13 et al.,1999) . Titers expressed as viral genomes per ml were: rAAV2/1-rtTAM2-WPRE-EGFP, 14 1.7 X 10 11 ; rAAV2/1-rtTAM2-EGFP, 2 X 10 11 , rAAV2/1-CMV-EGFP, 2.0 X 10 11 , rAAV1-15 rtTAM2-GDNF, 7.0 X 10 11 . 16
17
Stereotaxic injections 18
Adult female Wistar rats of 250g (Harlan, Indianapolis, Indiana) were used for unilateral 19 intracerebral injections as previously described (Tenenbaum et al., 2000) . The animals were 20 anesthetized using a mixture of ketamine (Ketalar, Pfizer, New York City, NY; 100 mg kg -1 21 ip) and xylazin (Rompun, Bayer, Leverkusen, Germany; 10mg kg -1 ip). Injections were made 22 according to coordinates defined by Paxinos and Watson (Paxinos and Watson, 1997) 
using a 23
Kopf stereotaxic apparatus (David Kopf, Tujunga, California) . The injection coordinates were 24 respectively for the striatum, 0.5 mm anterior, 2.8 mm lateral to bregma and 5 mm below the 25 dural surface and 5.3 mm posterior, 2.2 mm lateral to bregma and 6.6 mm below the dural 26 surface for the midbrain. Viral particles diluted in 2 µl D-PBS (BioWittaker, Walkersville, 1 MD) were infused using a motor-driven Hamilton syringe (Bonaduz, Switserland; 0.2 µl/ 2 min.) with a 30G needle. After injection, the needle was left in place for 5 minutes in order to 3 allow diffusion of the viral suspension in the parenchyma. The needle was then slowly lifted 1 4 mm up and left in place 5 minutes, then slowly removed. Since after the surgery, the animals 5 were given water containing 3% sucrose and doxycycline (600 µg/ml or 1g/l for qPCR 6 analysis). 7
Animals were killed at the indicated time after surgery by an overdose of anesthetic (200 mg 8 kg -1 ketamine and 20 mg kg -1 xylazine). For immunohistological analysis, animals were 9 perfused through the ascending aorta first with 150-200 ml of saline (NaCl 0.9%), then with 10 300 ml 4% paraformaldehyde in 0.1M phosphate buffer (PF4). After overnight post-fixation 11 in PF4 at 4°C, brains were transferred to phosphate buffer saline (PBS) and stored at 4°C. 12
13
GDNF ELISA assay 14
For determination of GDNF brain tissue levels, animals were decapitated and the brains were 15 removed, gradually frozen in isopentane/dry ice (-10°C for 10 sec. then -20°C for 20 sec.) and 16 stored at -80°C. Two hundred micron coronal slices were cut using a cryostat and striata and 17 midbrains were dissected out, weighed and processed for ELISA assay. Tissue was sonicated 18 (Branson Sonifier 250, output 2, 30% duty cycle, 10 sec(Branson Ultrasonics, Danbury, CT) 19 in M-Per buffer (Pierce, Thermo Fisher Scientific Inc., Rockford, IL) supplemented with 20 protease inhibitors cocktail (Boehringer Ingelheim GmbH, Ingelheim, Germany). Samples 21 were centrifuged at 10,000 x g and supernatants were harvested and their protein 22 concentration analysed using the BCA Assay kit (Pierce, Thermo Fisher Scientific Inc., 23 Rockford, IL). GDNF tissue levels were measured according to the manufacturer's protocol 24 (BioSource, Nivelles, Belgium) and expressed in pg per mg of tissue. Recombinant human 25
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4
Immunofluorescence 5
Coronal sections (50 µm) obtained using a vibratome (Leica Microsystems, Wetzlar, 6 Germany) were sequentially incubated in: i) THST (50mM Tris, 0.5 M NaCl, 0.5% Triton 7 X100 (Merck, Frankfurter, Germany) pH7.6) containing 10% horse serum for 2 hours.; ii) 8 rabbit anti-GFP IgG (1:3000, Molecular Probes, Invitrogen, Carlsbad, CA) diluted in THST 9 containing 5% horse serum for 16 hours at 4°C; iii) donkey anti rabbit IgG conjugated with 10 biotin (Amersham, GE Healthcare, Munich, Germany) diluted 1:600 in THST containing 5% 11 horse serum, 2 hour at room temperature; iv) streptavidin conjugated to cyanine 2 (1:300; 12 Jackson ImmunoResearch, West Grove, PA) in THST containing 5% horse serum, 2 hours at 13 room temperature. Three washings in TBS (Tris 10mM, NaCl 0.9%, pH7.6) of 10 min. were 14 performed between each step. 15
For double immunofluorescence, these incubations were combined with mouse monoclonal 16 antibodies Chemicon, Millipore, Billerica, MA) ; anti-glutamic acid 17 decarboxylase (1:200, Chemicon, Millipore, Billerica, MA); anti-parvalbumin (1:2000, 18 Sigma-Aldrich, St Louis, MO) or anti-glial fibrillary acid protein (GFAP, 1:200, Chemicon, 19 Millipore, Billerica, MA)) (step ii); and donkey anti-mouse IgG coupled to cyanine 3 (1:200; 20 Jackson ImmunoResearch, West Grove PA) in THST containing 5% horse serum) (step iv). 21
For DARPP-32/GFP immunofluorescence, a mouse monoclonal anti-gfp antibody (a gift from 22 J.D.Franssen, Euroscreen, Gosselies, Belgium) at a 1:50 dilution was combined with rabbit 23
anti Chemicon, Millipore, Billerica, MA) in THST containing 5% 24 horse serum 16 hours at 4°C (step ii). The primary antibodies were detected using a donkey 25 Page 8 of 46  Human Gene Therapy   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 anti-rabbit IgG conjugated with biotin (1:200, Amersham, GE Healthcare, Munich, Germany) 1 and a goat anti-mouse IgG conjugated with horseradish peroxidase (HRP) antibody (1:100, 2 from tyramide signal amplification (TSA) kit, Molecular Probes, Invitrogen, Carlsbad, CA) 3 diluted in Blocking Reagent provided by the TSA kit (Molecular Probes, Invitrogen, 4
Carlsbad, CA), 1 hour at room temperature (step iii).
Step iv was performed as described 5 above.
Step v: the monoclonal anti-gfp then revealed using the TSA kit according to 6 manufacturer's protocol. 7
Sections were mounted using FluorSave mounting fluid for fluorescence (Calbiochem, 8 Merck, Frankfurter, Germany) and photographed using a Zeiss Axiophot 2 microscope 9 equipped with FITC and TRITC filters (Car Zeiss, Göttingen, Germany) as well as an 10
AxioCam digital camera (Carl Zeiss, Gottingen, Germany). Images were acquired as jpeg 11 files using the KS300 software (Car Zeiss, Gottingen, Germany). 12
13
Confocal microscopy 14
Co-labelling analysis were performed on pictures taken on at least three different sections 15 within the transduction zone using an automatic image analysis system (Lasersharp version 16 3.2 (Biorad, Hercules, CA) coupled to Axiovert 100 microscope, (Carl Zeiss, Gottingen, 17 Germany)). Pictures were then processed and analysed with the Image J software (NIH, 18
USA) 19 20
Stereology 21
The number of GFP-positive cells and the volume of the labelled brain area were evaluated by 22 stereological procedures based on the Cavalieri principle (Sterio, 1984) . For each animal, 23 serial sections with an interval of 500 µm were analyzed by means of the optical fractionator 24
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For GFP stainings, cryostat sections (50 µm) were sequentially incubated in: i) 3% H 2 O 2 in 5 TBS (Tris 10mM, 0.9% NaCl, pH7.6) for 30 min.; ii) THST (50mM Tris, 0.5 M NaCl, 0.5% 6 Triton X100 pH7.6) containing 10% horse serum for 1 hour.; iii) rabbit anti-GFP IgG 7 (Clonetech, Palo Alto, CA) diluted 1:3000 in THST containing 5% horse serum overnight at 8 4°C; iv) donkey anti rabbit IgG conjugated with biotin (Amersham, GE Healthcare, Munich, 9
Germany) 1:600 in THST containing 5% horse serum, 2 hours at room temperature. The 10 peroxidase staining was revealed using the ABC Elite vectastain kit and diaminobenzidine 11 (Vector, NTL Laboratories, Brussels, Belgium), according to the manufacturer's protocol. 12
Sections were mounted on gelatin-coated slides, dehydrated and mounted using DPX 13 mounting fluid (Sigma-Aldrich, St Louis, MO). Sections were photographed using a Zeiss 14 Axiophot 2 microscope (Carl Zeiss, Gottingen, Germany). 15
For CD5 and CD11b stainings, an identical protocol was used for steps i) and ii), then 16 sections were incubated with mouse anti-CD5 IgG (1:500, Serotec, MorphoSys, Dusseldorf, 17 Germany) or mouse anti-CD11b IgG (1:500, Serotec, MorphoSys, Dusseldorf, Germany) 18 (step iii), then goat anti-mouse IgG conjugated with HRP (Molecular Probes, Invitrogen, 19 Carlsbad, CA, from TSA kit) diluted in Blocking Reagent provided with the TSA kit 20 (Molecular Probes, Invitrogen, Carlsbad, CA) was added for 2 hours at room temperature 21 (step iv); and v) diaminobenzidine (Vector, NTL Laboratories, Brussels, Belgium), according 22 to the manufacturer's protocol. Sections were photographed using a Zeiss Axiophot 2(Carl 23
Zeiss, Gottingen, Germany) microscope and optical density of defined regions at short 24 distance from the needle tract (10 µm) measured using the Image J Software (NIH, USA). 25
Page 10 of 46 Human Gene Therapy   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 The ratio of the mean optical densities of 3 sections on the injected side and symmetrical 1 sections on the intact side was taken as a measure of microglial cells activation (CD11b) or T 2 cells infiltration (CD5) induced by vector injection and transgene expression. 3 4 Tissue sample collection 5 Animals injected with 4.0 X 10 8 viral particles of rAAV2/1-rtTAM2-EGFP or rAAV2/1-6 CMV-EGFP were anesthetized using an overdose of anesthetic (200 mg kg -1 ketamine and 20 7 mg kg -1 xylazine i.p.) and then decapitated. The brains were dissected out and frozen to -20°C 8 in a bath of methyl-butane using dry ice, before transfer to -80°C for conservation. The brains 9
were equilibrated 1 hour at -20°C before being sliced into 1 mm thick sections using a brain 10 matrix (Alto, Roboz, Gaithersburg, MD). Tissue punches corresponding to the substantia 11 nigra or to the dorsal midbrain were collected from 3 slices around the injection site. Samples 12
were then kept at -80°C before RNA and Hirt DNA extraction. Tissue samples (approx. 10 mg) were homogenized in 300 µl lysis buffer (Tris 10 mM pH 21 8.0, EDTA 10 mM, SDS 1%) containing 1 µl of DNase-free RNase (10 mg/ml; Roche 22
Applied Bioscience, Basel, Switserland) and Proteinase K (Roche Applied Bioscience, Basel, 23 Switserland) were added to final concentrations of 0.5 and 1 mg/ml, respectively. The 24 reaction was continued for 120 min at 37°C, after which NaCl was added to a final 25 We have previously shown that the rAAV2/1-tetON vector drives doxycycline (dox)-6 dependent GDNF expression in the rat striatum (Chtarto et al., 2007) . We have extended 7 these data and shown that the striatal amount of GDNF could be modulated in function of the 8 dox dose (Fig. 1) . 9
Since GDNF is secreted, it does not allow an immuno-histological identification of 10 transduced cells. Therefore, in the present study, we have used vectors expressing GFP, which 11 have an intracellular localisation. 12
Four 10 8 viral particles of crosspackaged rAAV2/1-rtTA-M2-WPRE-EGFP and rAAV2/1-13 CMV-EGFP were infused into the right striatum of adult rats. 14 GFP-positive cells were observed in a widespread region of the forebrain (Fig.. The CMV vector lead to GFP expression in relatively more astrocytes (5.9 ± 1.9 % of GFP-4 positive cells) than the tetON vector (1.2 ± 2.2%) (p < 0.05; Fig.3b) . 5 6 1.2.Anterograde transport to the globus pallidus and substantia nigra pars reticulata 7 GFP-positive fibers were observed in the substantia nigra pars reticulata (SNr) after 8 intrastriatal injection of the CMV (Fig. 4a) but not of the tetON vector (data not shown). 9
These GFP-positive fibers were co-labeled using an antibody directed toward glutamic acid 10 decarboxylase (GAD) (Fig. 4a ) characterizing the efferent projections of striatal gaba-ergic 11 inhibitory neurons. These data suggest that striato-nigral gaba-ergic projection neurons were 12 efficiently expressing GFP when using the CMV but not the tetON vector. It should be noted 13 that using a sensitive peroxidase biotin/streptavidin amplified immunohistochemistry for 14 GFP, stained fibers could be evidenced in the SNr of rAAV2/1-tetON-injected animals ( Fig.  15 4b). The staining was however weaker than for the CMV vector (Fig. 4b) . To compare the 16 intensity of the stainings, the ratio of the mean optical densities of 3 sections on the injected 17 versus intact sides was taken as a measure of fiber density and was found to be significantly 18 lower for the tetON vector (Fig. 4c) . The extent of the staining was also more restricted for 19 the tetON vector. Indeed, it covered a smaller part of the SNr (Fig.4b) . The antero-posterior 20 distribution of the labeled region was similar for both vectors (data not shown). 21
Accordingly, intrastriatal injection of AAV2/1 vectors expressing the GDNF cDNA, resulted 22 in low amounts of GDNF (not significantly higher than the endogenous level) in the 23 substantia nigra (Fig.1) . 24 In contrast, GFP-positive projections of DARPP-32-positive gaba-ergic neurons in the globus 1 pallidus were evidenced with both the CMV and the tetON vector ( Fig. 4b ) and the fiber 2 densities were not significantly different for the 2 vectors (Fig. 4c) . animal; n=3) co-labeling with the dopaminergic neuron marker tyrosine hydroxylase were 7 evidenced in the SNpc (Fig. 5) , suggesting that rAAV2/1 viral particles were retrogradely 8 transported from the injection site in the striatum to the SNpc. In contrast, no GFP-positive 9 cell was detected by immunofluorescent labeling in the tetON vector group (data not shown). 10
To determine if a weak GFP expression from the tetON vector could be evidenced using a 11 more sensitive detection technique, midbrain sections were labeled by immunohistochemistry 12 for GFP using a sensitive biotin-streptavidin amplification step (see Material and Methods). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 and Lim, 2004) could possibly be transduced, we examined the olfactory bulbs for GFP 1 expression. We detected numerous GFP-positive cells (5406.7±5049.9 per animal; n=3), 5 2 weeks after intrastriatal injection of rAAV2/1-CMV-EGFP ) ( Fig. 6c) but not rAAV2/1-rtTA-3 M2-WPRE-EGFP (2.0±2.7 per animal; n=3) (data not shown). 4 5
Immune response 6
Markers for infiltrating lymphocytes (CD5) and microglial cells (CD11b) were absent or 7 restricted to the needle tract for both rAAV vectors, whereas a strong labeling for both 8 markers was observed after injection of an adenoviral vector expressing LacZ . The ratio of 9 the mean optical densities of 3 sections on the injected side and intact sides was taken as a 10 measure of microglial cells activation (CD11b) or T cells infiltration (CD5) induced by vector 11 injection and transgene expression (data not shown). The optical density of sections labeled 12 for the astrocytic marker GFAP (known to be upregulated during inflammation) was also 13 similar for sham-injected animals and for both AAV vectors (data not shown). 14 15
Midbrain Injections 16
Substantia nigra pars compacta 17
Four 10 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 EGFP : data not shown). For the 3 vectors, the GFP-positive area covered the entirety of the 1
SNpc and VTA. 2
To analyze the specificity and the efficiency of rAAV2/1 vectors for dopaminergic neurons of 3 the SNpc, colabeling for GFP and tyrosine hydroxylase (TH) was performed. Double-labeled 4 cells were identified by confocal microscopy. For each animal a total number of about 150 5 cells was counted in 3 sections at 250-µm intervals, taken around the injection site. In order to address the mechanism of the observed differential biodistribution of GFP protein 18 with the CMV and tetON vectors, the gfp mRNA and DNA were quantified in the substantia 19 nigra and in the dorsal midbrain. Hirt low molecular weight DNA (hDNA) (Hirt, 1967) and 20 messenger RNAs (mRNA) were extracted from tissue punches and mRNAs were converted to 21 cDNA. Real-time quantitative PCR showed that the levels of gfp transcripts normalized 22 versus the levels of two different house keeping genes (YWHAZ and actin 2) and relative to 23 the levels of hDNA were significantly higher (5-fold; p=0.0074) in the SN versus the 24 midbrain (Fig.8) . A ~2.5-fold higher relative level of gfp transcripts in the SN versus the 25 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 midbrain was also observed for the CMV vector (Fig.8) . However, the difference was not 1 statistically significant (p=0.086). 2 3 2.2 Striatum 4 GFP-postive fibers were evidenced in the striatum (Fig.9) suggesting that GFP was 5
anterogradely transported from dopaminergic cell bodies of the SNpc to dopaminergic fibers 6 in the striatum. 7 are: a widespread distribution of the neurotrophic factor in the putamen, the absence of 4 significant amounts of transgene product in connected regions which can induce adverse 5 effects as well as an optimal dose of the neurotrophic factor providing neuroprotection in the 6 absence of other, undesired biological effects. 7
We have previously shown that a single injection of the autoregulatory rAAV2/1-8 tetON vector drives doxycycline-dependent GDNF expression in a widespread area of the rat 9 striatum (Chtarto et al., 2007) . We have extended these data and shown that the striatal 10 amount of GDNF could be modulated in function of the doxycycline dose. The GDNF 11 concentrations (~33 and 75 pg/mg tissue at doxycycline doses of 300 and 600 mg/l of 12 drinking water, respectively) were similar to that obtained by Eslamboli and coll. (Eslamboli 13 et al., 2005) , i.e. 40 pg/mg tissue, providing neuroprotection and behavioural improvements in 14 the absence of effects on the dopamine metabolism. 15
In the present study, we compared the biodistribution and cellular tropism of 16 rAAV2/1-tetON-EGFP and rAAV2/1-CMV-EGFP in the striatum and in the midbrain. 17
After striatal injection, although the vast majority of the GFP-positive cells were 18 neurons with both vectors, the percentage of GFP-positive astrocytes was significantly higher 19 when using the CMV vector. Furthermore, a different subset of neurons was expressing GFP 20 when using the tetON and the CMV vectors. Indeed, while rAAV2/1-CMV-EGFP expressed 21 the transgene in parvalbumin-positive interneurons and DARPP-32 projection neurons in 22
proportions roughly reflecting the presence of these two subpopulations of neurons (the vast 23 majority, i.e. 90-95%, of striatal neurons being DARPP-32-positive medium spiny projection 24 neurons) (Graveland and DiFiglia, 1985) , rAAV2/1-tetON-EGFP targeted transgene 25
Page 20 of 46 Human Gene Therapy   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 expression in proportionally more parvalbumin-immunoreactive neurons (approx. 1 1 parvalbumin-positive for 2 DARPP-32-positive neurons). In addition, among DARPP-32 2 immunoreactive neurons, those projecting to the globus pallidus were expressing GFP 3 similarly with both vectors, whereas those projecting to the substantia nigra pars reticulata 4 were expressing GFP with the CMV but much less efficiently by the tetON vector as 5 evidenced by the GFP-positive projections observed in these structures. Retrograde transport 6 of viral particles from the striatum to the SNpc has been already reported with rAAV2/1 7 vectors using the CBA (Burger et al., 2004) and the CMV promoters (Wang et al., 2003) . The 8 present study confirms retrograde transport when using the CMV promoter. However, it was 9 inefficient (approx. 100 cells per animal) as compared to the number of transduced cells 10 around the delivery site in the striatum (approx. 100,000 per animal). In contrast, only few 11 weakly labeled GFP-positive cells were detected in the SNpc of animals injected with 12 rAAV2/1-tetON in the striatum. This could be due to a limited transgene inducibility in 13 dopaminergic neurons. However, after direct injection in the midbrain, very efficient GFP 14 expression in tyrosine hydroxylase-positive neurons was obtained with both vectors. 15
Altogether these data could suggest that high multiplicities of rAAV-tetON are required to 16 obtain an intracellular concentration of transactivator sufficient to induce the tetON system 17 and that the threshold number of viral genome copies could not be reached after retrograde 18 transport. Additional experiments, using for example labeled capsids, will be necessary to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Indeed, although both vectors very efficiently expressed GFP in the SVZ, numerous GFP-1 positive cells were evidenced in the olfactory bulb (in which neural stem cells of the SVZ 2 migrate and differentiate (Alvarez-Buylla and Lim, 2004)) 5 weeks after injection of 3 rAAV2/1-CMV-EGFP but not rAAV2/1-tetON-EGFP. The absence of GFP-positive cells in 4 the olfactory bulb suggests that either the cells migrating to the olfactory bulb did not express 5 a detectable level of GFP due to low transcription efficiency or gene expression from the tet-6 responsive promoter was switched-off during migration and/or differentiation of neuroblasts. 7
The full characterization of initially-infected cells in the SVZ will require analysis shortly 8 after infection, before migration takes place. Regardless, the lack of GFP expression in the 9 migrating neuroblasts together with the efficient GFP expression in the neighbouring cells in 10 the SVZ, suggests that the rAAV2/1-tetON-EGFP could be used to express diffusible factors 11 acting in a paracrine way on neural stem cells while avoiding transgene expression in 12 olfactory bulb neurons. 13
Altogether, the data obtained after striatal injection support the potential use of 14 rAAV2/1-tetON for Parkinson's disease GDNF gene therapy. Indeed, the inefficient 15 retrograde transport of rAAV2/1 to the SNpc and anterograde transport of the transgene 16 product to the SNr, ensure a minimal amount of GDNF in the SN after striatal viral delivery. 17
Since the presence of high amounts of GDNF in the SN has been associated with aberrant 18 sprouting (Georgievska et al., 2002) , the here described vector constitutes a safer alternative 19 for striatal GDNF gene delivery. In addition, the absence of transgene expression in the 20 olfactory bulb despite transduction of the subventricular zone when using the tetON but not 21 the CMV promoter-bearing rAAV2/1 vector, also renders the former safer than the latter. 22
Another important finding of this study is that, after injection in the midbrain, 23 rAAV2/1 vectors using the autoregulatory tetON transcription cassette provides preferential 24 transgenic expression in tyrosine hydroxylase-immunoreactive neurons of the substantia nigra 25 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 pars compacta and ventral tegmental area. This property will be useful to evaluate the 1 function of genes potentially involved in the etiology of Parkinson's disease as well as in the 2 physiology of dopaminergic neurons. Quantification of gfp transcripts relative to the amounts 3 of viral DNA evidenced a 5-fold higher expression level in the substantia nigra versus the 4 dorsal midbrain. Recombinant AAV2/2 vectors using constitutive promoters also efficiently 5 drive transgene expression into dopaminergic neurons when injected in the midbrain (Kirik et 6 al., 2002; Burger et al., 2004) . Kirik and coll. (Kirik et al., 2002) using the CBA promoter 7 reported that the expression profile was not restrictive to dopaminergic neurons of the 8 substantia nigra pars compacta and ventral tegmental area but also affected the pars reticulata 9 of the substantia nigra and the mesensephalic reticular formation. 10
We can not exclude that the Woodchuck Hepatitis Virus Post-transcriptional 11
Regulatory Element (WPRE) could contribute to the observed transgene expression profile. 12 Indeed, the WPRE sequence has been reported to contain enhancer activity (Kingsman et al., 13 2005) . Furthermore, it has been shown to enhance the transgene expression efficiency from 14 rAAV2/2 vectors using different cellular (Paterna et al., 2000) and viral (Passini et al., 2003) 15 promoters. Whether the WPRE sequence modifies the cellular specificity of these vectors has 16 not been studied. In the present study, the WPRE sequence, placed downstream to the rtTA-17 M2 transactivator coding sequence did not significantly modify neither the efficiency nor the 18 profile of trangene expression from the autoregulatory AAV-tetON vector in the SNpc. These 19 data are in accordance with a previous study using the same vectors expressing the GDNF 20 cDNA (Chtarto et al., 2007) , in which we have shown that the WPRE sequence did not 21 modify the GDNF tissue levels in the induced (+ doxycycline) state but resulted in a higher 22 basal level of GDNF expression (-doxycycline). It could be that, the potentially increased 23 rtTAM2 expression in the rAAV2/1-rtTA-M2-WPRE relative to the rAAV2/1-rtTA-M2 24 vector, results in an increased expression of the transgene under the control of the 25 tetracycline-responsive promoter in the non-induced but not in the induced state. In favour of 1 this hypothesis, the rtTA-M2 transactivator harbour a high affinity for doxycycline and a 2 higher stability in eukaryotic cells than the original rtTA, suggesting that it might saturate the 3 tetracycline operator sites in the induced state not allowing further improvements by 4 increasing its intracellular concentration. 5
Overall, the restricted transgene expression of rAAV2/1-tetON as compared to 6 rAAV2/1-CMV could be due to i) lack of activation of the tetON system in cells which do not 7 accumulate enough transactivator in the absence of tetracycline; ii) absence of cellular factors 8 binding to the VP16 activation domain of the rtTA; iii) inefficient penetration or rapid 9 metabolisation of doxycycline in cells not expressing the transgene. However, some cell types 10 were expressing GFP as efficiently (TH-positive SNpc neurons) or more efficiently 11 (parvalbumin-immunoreactive striatal neurons) by the tetON than by the CMV vector. 12 Differential transgene expression profiles of rAAV2/2-CMV and rAAV2/2-tTA 13 (tetOFF) has also been reported (Haberman et al., 2002) . The authors showed that the same 14 transgene had opposite functional effects when expressed respectively under a CMV or 15 tetOFF transcriptional control and demonstrated using a gfp and a lacZ reporter gene 16 respectively, that the vectors were expressed mainly in different subpopulations of neurons. 17
Immune reaction is a major issue in gene therapy. The rtTA-M2 transactivator is a 18 composite protein harbouring a viral as well as bacterial subdomains. Several studies report 19 immune responses directed against the rtTA after injection of tetracycline-regulatable viral 20 vectors in the muscle (Favre et al., 2002) . However, in the brain of healthy animals, no 21 cellular immune reaction to the tTA/rtTA transactivator has been described using rAAV2/2 22 and adenoviral vectors (Fitzsimons et al., 2001; Xiong et al., 2008) . These conclusions were 23 confirmed in the present study using rAAV2/1 pseudotyped vectors. In addition Xiong and 24 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 coll. showed that systemic immunity against the rtTA-M2 transactivator did not lead to 1 inflammation or reduction of transgene expression in the striatum (Xiong et al., 2008) . 2
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In conclusion, targeted transgene expression in specific brain cell populations might be 3 achieved by a combination of local injection and adequate choice of serotype and promoter. In 4 this respect, the here described rAAV2/1-tetON vector is an interesting tool i) to study the 5 function of genes in dopaminergic neurons of the SNpc; ii) to conditionally deliver diffusible 6 factors in the subventricular zone for the paracrine modification of neural stem cells. In 7 addition, regulatable transgene expression in the SNpc is of great interest for the study of the 8 function of Parkinson's disease-related genes such as -synuclein, Parkin, etc… in order to 9 characterize and distinguish permanent and reversible effects of the overexpression of the 10 wild-type and mutated forms of these genes. 11
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